Takeda Pharmaceutical Company Limited (TAK)

業務介紹

武田藥品工業株式會社從事藥品的研究、開發、製造、行銷和授權業務,業務範圍涵蓋日本、美國、歐洲、加拿大、拉丁美洲、俄羅斯、亞洲其他地區以及國際市場。該公司提供的藥品涵蓋胃腸科、罕見疾病、血漿衍生療法、腫瘤學和神經科學等領域。該公司的產品包括Entyvio、Gattex/Revestive、Takecab、Alofisel、Dexilant、Natpara、Adynovate/Adynovi、Takhzyro、Livtencity、Elaprase、Replagal、Advate、Vpriv、Gammagard Liquid/Kiovig、Hyqvia、Cuvitru、Exkivity、Velcade、Leuplin/Enantone、Adcetris、Vyvansese、Trintellix和Alunbrig等品牌。武田藥品工業株式會社與Neurocrine Biosciences, Inc.有授權協議;與德克薩斯大學MD安德森癌症中心、箭頭製藥公司和Ovid Therapeutics Inc.有合作和授權協議;與Evox Therapeutics Ltd.有合作關係,並與ProThera Biologics Inc.有授權協議。該公司還與Crescendo Biologics、Code Bio、Immusoft、Poseida Therapeutics、Selecta Biosciences、BridGene Biosciences、Skyhawk Therapeutics和StrideBio有研究合作和授權協議;與Egle Therapeutics SAS、Evotec SE、Neurocrine Biosciences, Inc.、Carmine Therapeutics、KSQ Therapeutics和Anima Biotech有戰略聯盟。武田藥品工業株式會社成立於1781年,總部位於日本東京。



Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

公司網址

https://www.takeda.com